PLP defects

A central problem in PLP1 research is translating genotype-level molecular heterogeneity into quantifiable functional outcomes. PLP1 duplications – the most common PMD genotype – produce early-onset, severe hypomyelination driven by toxic PLP1 overexpression and ER stress-induced oligodendrocyte death. PLP1 missense mutations cause misfolded protein retention in the ER, also activating the unfolded protein response with a phenotypic severity correlated with the degree of ER retention. PLP1 null mutations, by contrast, allow near-normal oligodendrocyte survival and myelination but lead to progressive, length-dependent axon degeneration in the second decade of life, reflecting PLP1’s non-structural role in supporting axonal metabolic homeostasis via oligodendrocyte-axon coupling. Clinically, this produces a mild PMD/SPG2 syndrome in humans and a comparable pattern in Plp1 knockout mice (Garbern et al., Acta Neuropathol, 2009). The optic nerve captures all three mechanisms because it is a long, PLP1-dependent white matter tract that is hypomyelinated in duplication/missense cases and subject to progressive axon degeneration in null cases. Standard histological endpoints require sacrifice; electrophysiology (VEP) and ERG require anaesthesia and surgical preparation. Neither is amenable to high-frequency longitudinal monitoring across disease progression in the same animal. For researchers also studying autoimmune demyelinating conditions, see Autoimmune Demyelinating Diseases for cross-model comparison approaches.

A 2022 review by Massaad et al. summarising the full PLP1 clinical-genetic spectrum noted that visual phenotypes including nystagmus and delayed VEP latency are present across all PMD genotypes, establishing the visual pathway as a common readout for genotypically heterogeneous disease (Massaad et al., Biomedicines, 2022). Preclinical researchers require tools that can track the corresponding optomotor acuity trajectory in mice across multiple ages and mutation types without the confound of anaesthesia-induced changes in neurological state.

A central unresolved question in demyelinating disease biology is whether microglia-mediated myelin removal is a cause of axon damage (the conventional view) or a protective clearance mechanism that prevents worse secondary pathology from aberrant myelin debris. In PLP1-deficient and PLP1-mutant models, where myelin is either absent or abnormal, microglia accumulate around hypomyelinated axon segments and begin removing myelin fragments. The standard interpretation has been that this microglial activity is inflammatory and injurious. However, the architecture of the PLP1-deficient CNS means that retained abnormal myelin, rather than its removal, may be the proximate cause of axon damage – placing microglial clearance in a neuroprotective role. Distinguishing between these possibilities in vivo requires a functional endpoint that is sensitive to axon integrity in the optic nerve, measured longitudinally, and interpretable independently of motor dysfunction that would confound standard behavioural endpoints. For researchers working on immune mechanisms in related acquired demyelinating conditions, see Autoimmune Demyelinating Diseases and Neuroinflammation and Autoimmune CNS Disease for comparative context on microglial roles. For a focused overview of optic nerve-specific damage mechanisms across disease types, see Axon Degeneration.

The optic nerve is ideal for this question because it is a spatially discrete, PLP1-dependent white matter tract that is accessible to combined functional (OptoDrum, VEP) and structural (electron microscopy, immunohistochemistry) endpoints. A functional assay that tracks visual acuity longitudinally in the same animals before and after pharmacological or genetic microglial manipulation allows researchers to determine whether microglial ablation or activation worsens or improves the circuit-level outcome.

A growing body of evidence implicates cytotoxic CD8+ T cells in the secondary neuroinflammatory pathology of progressive MS and rare leukodystrophies. In PLP1 disease, the question of whether the eventual visual and neurological deterioration reflects purely the primary oligodendrocyte-autonomous defect or also a secondary adaptive immune attack is directly relevant to therapeutic strategy: if cytotoxic T cell infiltration is driving a meaningful component of axon degeneration and functional loss, then immunomodulatory approaches targeting this adaptive immune effector arm are a rational adjunctive strategy alongside myelination rescue. Answering this question requires an endpoint that specifically captures the functional consequence of axon degeneration in an accessible circuit, separate from motor dysfunction that could reflect corticospinal tract damage. Visual pathway degeneration in the optic nerve – a CNS white matter tract with a direct, quantifiable functional output via optomotor testing – is well positioned for this purpose. For broader context on adaptive immune contributions to CNS disease, see Neuroinflammation and Autoimmune CNS Disease. For ocular immune-mediated damage mechanisms in related conditions, see Ocular Inflammation and Immune-Mediated Eye Disease. For a focused overview of the axon degeneration mechanisms common across inherited and acquired CNS disease, see Axon Degeneration and Neuroinflammation. For researchers working specifically on rare inherited disease, see Rare Disease.

Separating the CTL-driven component from the oligodendrocyte-intrinsic defect requires animal models in which T cell infiltration can be manipulated genetically or pharmacologically while the background PLP1 mutation remains constant. In such experiments, OptoDrum provides a quantitative visual acuity endpoint that can detect a functionally significant change in circuit integrity when CTL-mediated axon damage is superimposed on the pre-existing hypomyelination.

Preclinical therapeutic development for PMD requires knowledge of the therapeutic window – the period during which intervention can prevent functional loss rather than merely slow irreversible damage. Oligodendrocyte ER stress begins early in PLP1 duplication and missense models, and once oligodendrocyte death has occurred, remyelination requires progenitor recruitment that may be insufficient in the severely affected CNS. In PLP1-null/SPG2 models, by contrast, the slow progressive axon degeneration provides a wider therapeutic window, but detecting early-stage axon loss before clinical manifestation requires sensitive, longitudinal endpoints. Visual function testing via OptoDrum provides such an endpoint: it is sensitive to both myelin deficiency (early stage) and secondary axon loss (later stage), is fully non-invasive, and can be applied at weekly intervals from weaning without affecting animal welfare or disease course. Importantly, ASO-mediated Plp1 suppression in jimpy mice has been shown to rescue myelination and extend lifespan, demonstrating that functional rescue is achievable if the therapeutic window is identified correctly (Nevin et al., bioRxiv, 2018). Integrated stress response inhibition by PERK pathway modulators was recently shown to extend oligodendrocyte survival and lifespan in PMD mice (Tiwari et al., Nat Commun, 2025). For therapeutic approaches across inherited CNS disease, see also Rare and Inherited CNS and Eye Disorders.

While the severe PMD end of the PLP1 spectrum (duplication, jimpy-type mutations) has received significant preclinical attention, the SPG2 end – characterised by PLP1 haploinsufficiency or null mutations – is mechanistically distinct and clinically important. SPG2 patients present with progressive spastic paraparesis, mild intellectual disability, and peripheral neuropathy; visual involvement tends to be subtle clinically but measurable by VEP, with prolonged or absent responses reported in some patients reflecting subclinical optic neuropathy. In mice, Plp1 knockout animals develop an essentially normal appearance until several months of age, when slow Wallerian degeneration of long CNS axons – including optic nerve fibres – begins. This slow progression creates a therapeutic window, but also means that functional endpoints need to be sensitive to gradual changes detectable before clinical presentation. Histological axon counting requires sacrifice; VEP requires anaesthesia. OptoDrum testing in Plp1-knockout mice offers a non-terminal functional indicator of the progressive optic nerve axon degeneration characteristic of the SPG2 phenotype. For a broader framework on axon degeneration as a shared mechanism across CNS diseases, see Axon Degeneration. For context on rare inherited disease platforms more broadly, see Rare Disease.

A clinical study of SPG2 and PLP1-related disorders documented progressive corticospinal tract degeneration as the dominant feature, with optic nerve involvement in some pedigrees; the slow disease course in null patients is consistent with the gradual axon degeneration mechanism documented in mouse knockouts (Zhang et al., Ann Clin Neurol, 2023).